Telix Pharmaceuticals hits over 3-week high on US CMS designation for Gozellix

** Shares of Australia's Telix Pharmaceuticals TLX.AX rise as much as 22.1% to A$18.32, their highest since August 27

** Stock's biggest intraday pct gain since November 2, 2020

** Biopharmaceutical company says the U.S. Centres for Medicare & Medicaid Services have granted transitional pass-through payment status for Gozellix, an imaging agent for prostate cancer

** Designation allows for separate reimbursement for Gozellix under the hospital outpatient prospective payment system in the U.S., effective October 1 onwards

** Stock's biggest intraday pct gain since November 2, 2020

** Around 4.7 mln shares change hands, 1.4x the 30-day avg trading volume

** YTD, stock down 34.1% including the session's gains